Compound class:
Synthetic organic
Comment: TXA709 is an orally bioavailable prodrug of TXA707 (PubChem: 90135655), a benzamide antibacterial compound that inhibits the essential and conserved prokaryotic cell division protein FtsZ [3]. TXA709 is under clinical development, as a combination therapy with synergistic drug partners, for infections caused by methicillin-resistant Staphylococcus aureus (MRSA) [1-2].
|
|
References |
1. Kaul M, Ferrer-González E, Mark L, Parhi AK, LaVoie EJ, Pilch DS. (2022)
Combination with a FtsZ inhibitor potentiates the in vivo efficacy of oxacillin against methicillin-resistant Staphylococcus aureus. Med Chem Res, 31 (10): 1705-1715. [PMID:37065467] |
2. Kaul M, Mark L, Parhi AK, LaVoie EJ, Pilch DS. (2016)
Combining the FtsZ-Targeting Prodrug TXA709 and the Cephalosporin Cefdinir Confers Synergy and Reduces the Frequency of Resistance in Methicillin-Resistant Staphylococcus aureus. Antimicrob Agents Chemother, 60 (7): 4290-6. [PMID:27161635] |
3. Kaul M, Mark L, Zhang Y, Parhi AK, Lyu YL, Pawlak J, Saravolatz S, Saravolatz LD, Weinstein MP, LaVoie EJ et al.. (2015)
TXA709, an FtsZ-Targeting Benzamide Prodrug with Improved Pharmacokinetics and Enhanced In Vivo Efficacy against Methicillin-Resistant Staphylococcus aureus. Antimicrob Agents Chemother, 59 (8): 4845-55. [PMID:26033735] |
4. Taxis Pharmaceuticals.
Our Pipeline. Accessed on 22/03/2024. Modified on 22/03/2024. https://www.taxispharma.com/research-development/our-pipeline/ |